Nabriva Therapeutics (NBRV) Competitors

38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 2.7% of Precision BioSciences shares are held by company insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Precision BioSciences had 6 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 6 mentions for Precision BioSciences and 0 mentions for Nabriva Therapeutics. Precision BioSciences' average media sentiment score of 0.00 equaled Nabriva Therapeutics'average media sentiment score.

Precision BioSciences has higher earnings, but lower revenue than Nabriva Therapeutics. Precision BioSciences is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Precision BioSciences presently has a consensus price target of $36.33, indicating a potential upside of 387.70%. Given Precision BioSciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Precision BioSciences is more favorable than Nabriva Therapeutics.

Precision BioSciences has a net margin of -133.45% compared to Nabriva Therapeutics' net margin of -148.11%. Precision BioSciences' return on equity of -122.60% beat Nabriva Therapeutics' return on equity.

Precision BioSciences has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.

Hillstream Biopharma has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Hillstream Biopharma's return on equity of -35.59% beat Nabriva Therapeutics' return on equity.

Given Nabriva Therapeutics' higher probable upside, analysts plainly believe Nabriva Therapeutics is more favorable than Hillstream Biopharma.

1.2% of Hillstream Biopharma shares are owned by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are owned by institutional investors. 6.7% of Hillstream Biopharma shares are owned by insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Hillstream Biopharma has higher earnings, but lower revenue than Nabriva Therapeutics. Hillstream Biopharma is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

In the previous week, Hillstream Biopharma's average media sentiment score of 0.00 equaled Nabriva Therapeutics'average media sentiment score.

Hillstream Biopharma has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.

Alpha Teknova currently has a consensus target price of $8.00, suggesting a potential upside of 113.90%. Given Alpha Teknova's stronger consensus rating and higher probable upside, equities analysts plainly believe Alpha Teknova is more favorable than Nabriva Therapeutics.

13.8% of Alpha Teknova shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 12.5% of Alpha Teknova shares are held by insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Alpha Teknova has a net margin of -42.59% compared to Nabriva Therapeutics' net margin of -148.11%. Alpha Teknova's return on equity of -23.32% beat Nabriva Therapeutics' return on equity.

In the previous week, Alpha Teknova had 1 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 1 mentions for Alpha Teknova and 0 mentions for Nabriva Therapeutics. Alpha Teknova's average media sentiment score of 0.00 equaled Nabriva Therapeutics'average media sentiment score.

Alpha Teknova has higher revenue and earnings than Nabriva Therapeutics. Alpha Teknova is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Alpha Teknova has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500.

26.6% of Molecular Partners shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 5.9% of Molecular Partners shares are held by insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Molecular Partners has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.

Molecular Partners has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Molecular Partners' return on equity of -60.62% beat Nabriva Therapeutics' return on equity.

Nabriva Therapeutics has higher revenue and earnings than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Molecular Partners currently has a consensus target price of $8.38, indicating a potential upside of 90.56%. Given Molecular Partners' stronger consensus rating and higher possible upside, analysts clearly believe Molecular Partners is more favorable than Nabriva Therapeutics.

In the previous week, Molecular Partners had 3 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 3 mentions for Molecular Partners and 0 mentions for Nabriva Therapeutics. Molecular Partners' average media sentiment score of 0.62 beat Nabriva Therapeutics' score of 0.00 indicating that Molecular Partners is being referred to more favorably in the media.